Clinical Trial Update: TJ202 Combined With Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma [Phase 2]

View source ↗

Summary

Clinical trial update indicates completion of a Phase 2 study of TJ202 with dexamethasone in relapsed or refractory multiple myeloma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• DEXAMETHASONE (Dexamethasone)
• TJ202

Snippet

Sponsor: TJ Biopharma Co., Ltd. | Conditions: Multiple Myeloma in Relapse, Refractory Multiple Myeloma | Phase 2 | Status: COMPLETED